We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Ebola Vaccine Found to Protect Monkeys

By Biotechdaily staff writers
Posted on 13 Aug 2003
A study has shown that a single dose of a fast-acting experimental vaccine against the Ebola virus was able to protect monkeys from the virus after only one month. More...
The study was reported in the August 7, 2003, issue of Nature.

Researchers had been pursuing a "prime-boost” vaccine strategy against a variety of infectious diseases. Prime-boost is a two-part process that comprises an injection of noninfectious genetic material from the disease-causing microbe to prime the immune system to respond, and several weeks later, an injection of attenuated carrier viruses containing key genes from the microbe to substantially boost the immune response. The boost produces a weaker immune response but is quicker. Since time is critical when fighting Ebola, they decided to test whether the boost's fast response alone was strong enough to protect against the virus.

Eight monkeys were immunized with a single injection, consisting of attenuated carrier viruses containing genes for important Ebola antiens. The monkeys were then injected with an Ebola virus strain. The single vaccine injection completely protected all eight animals against Ebola infection, even those who received high doses of the virus. The study was conducted by scientists at the National Institute of Allergy and Infectious Diseases (NIAID) and the United States Army Medical Research Institute of Infectious Diseases at Fort Detrick, MD, USA).

"This research has enormous public health implications not only because it might be used to limit the spread of Ebola virus but also because this vaccine strategy may be applied to other highly lethal viruses, such as the Marburg and Lassa fever viruses and the SARS Coronavirus, that cause acute disease outbreaks and require a rapid response,” said Anthony S. Fauci, M.D., director of NIAID.




Related Links:
National Institute of Allergy and Infectious Diseases

New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Automatic Hematology Analyzer
CF9600
New
All-in-One Molecular System
AIO M160
New
Pipette Calibration System
Artel PCS®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The device contains specific antibodies that capture the primary biomarker of pancreatic cancer. The binding of these antibodies alters the distribution of electrical charges on the electrode surface. The sensor then translates this variation into a measurable capacitance signal (photo courtesy of Gabriella Soares / IFSC-USP)

Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection

Pancreatic cancer is frequently identified only after it has progressed because early disease is typically asymptomatic, and survival remains extremely poor once advanced. Conventional laboratory assays... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.